Ret Proto-Oncogene Antikörper

Produktnummer ABIN1882126

Produktdetails anti-Ret Proto-Oncogene Antikörper

Target: Ret Proto-Oncogene (RET)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Ret Proto-Oncogene Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Aufreinigung: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This RET antibody is generated from rabbits immunized with His fusion protein of human RET.

Klon: RB17715

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Haltbarkeit: 6 months

Referenzen für anti-Ret Proto-Oncogene Antikörper (ABIN1882126)

Siqueira, Romitti, da Rocha, Ceolin, Meotti, Estivalet, Puñales, Maia: "The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma." in: Endocrine-related cancer, Vol. 17, Issue 4, pp. 953-63, (2010) (PubMed).

Gockel, Schumacher, Gockel, Lang, Haaf, Nöthen: "Achalasia: will genetic studies provide insights?" in: Human genetics, Vol. 128, Issue 4, pp. 353-64, (2010) (PubMed).

Kim, Jung, Lim, Sung, Whang, Jo, Lee, Shin, Kim, Ryu, Kim: "A study of RET proto-oncogene polymorphisms in association with lung cancer risk in the Korean population." in: Anticancer research, Vol. 30, Issue 9, pp. 3621-7, (2010) (PubMed).

Pacini, Castagna, Cipri, Schlumberger: "Medullary thyroid carcinoma." in: Clinical oncology (Royal College of Radiologists (Great Britain)), Vol. 22, Issue 6, pp. 475-85, (2010) (PubMed).

Details zu Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Andere Bezeichnung: RET (RET Produkte)

Synonyme: c-ret antikoerper, cret antikoerper, etID315074.13 antikoerper, ret1 antikoerper, wu:fd13h01 antikoerper, X-ret antikoerper, ret-A antikoerper, xret antikoerper, RET antikoerper, MTC1 antikoerper, CDHF12 antikoerper, CDHR16 antikoerper, HSCR1 antikoerper, MEN2A antikoerper, MEN2B antikoerper, PTC antikoerper, RET-ELE1 antikoerper, RET51 antikoerper, RET9 antikoerper, c-Ret antikoerper, ret proto-oncogene receptor tyrosine kinase antikoerper, ret proto-oncogene S homeolog antikoerper, ret proto-oncogene antikoerper, ret antikoerper, ret.S antikoerper, RET antikoerper, Ret antikoerper

Hintergrund: This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their biological validity has not been confirmed.

Molekulargewicht: 124319

NCBI Accession: NP_065681, NP_066124

UniProt: P07949

Pathways: RTK Signalweg, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation